PepGen Reports Top Splicing Correction in DM1 Patients
September 25, 2025
PepGen Inc., a clinical-stage biotech company that focuses on creating advanced oligonucleotide therapies for severe neuromuscular and neurological diseases, recently shared positive clinical results from